Biorestorative Therapies, Inc. (NASDAQ:BRTX) Sees Large Drop in Short Interest

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 1,281,247 shares, a drop of 80.6% from the May 31st total of 6,588,718 shares. Currently, 5.8% of the company’s shares are short sold. Based on an average daily trading volume, of 1,895,030 shares, the days-to-cover ratio is currently 0.7 days.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BRTX. Virtu Financial LLC boosted its holdings in Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after purchasing an additional 12,319 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Biorestorative Therapies during the 3rd quarter valued at $152,000. Finally, DRW Securities LLC bought a new position in shares of Biorestorative Therapies during the 4th quarter valued at $55,000. Hedge funds and other institutional investors own 69.38% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Wednesday, May 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Biorestorative Therapies Stock Performance

BRTX traded down $0.01 during trading on Friday, reaching $0.38. The stock had a trading volume of 291,671 shares, compared to its average volume of 2,201,984. The business has a 50-day moving average of $0.30 and a 200-day moving average of $0.56. The stock has a market cap of $9.68 million, a PE ratio of -0.36 and a beta of 0.67. Biorestorative Therapies has a one year low of $0.16 and a one year high of $1.89.

Biorestorative Therapies (NASDAQ:BRTX) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. Biorestorative Therapies had a negative return on equity of 508.42% and a negative net margin of 3,088.27%.The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.31 million. Equities research analysts forecast that Biorestorative Therapies will post -0.66 EPS for the current fiscal year.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.